NEW YORK, April 3 – Phase-1 Molecular Toxicology has licensed its new toxicogenomic database, Toxbank, to Bayer, as part of a one-year extension of an existing collaboration with the pharmaceutical company, Phase-1 said Wednesday.
Under the agreement, Phase-1 of Santa Fe, NM, will provide consulting to Bayer in the area of molecular toxicology, and will grant Bayer full access to Toxbank, a database of more than 1,000 rat gene expression experiments. Toxbank also includes Matrixexpress, a custom software product for analyzing the gene expression experiments.
"We are very pleased about this vote of confidence from a major pharmaceutical company such as Bayer,” Spencer Farr, chief scientific officer of Phase-1, said in a statement. “We believe that our continuous focus on improving the breadth and quality of our services will strengthen our leadership position in molecular toxicology."
Phase-1, a privately owned company founded n 1995, launched the rat Toxbank database in January.
The company established a European office in Ghent, Belgium last year, and has formed other partnerships with Boeringher Ingleheim, Schering AG, and Berlex Biosciences for toxicological screening of potential drug candidates. The company also has a deal with Applied Biosystems to develop high-throughput gene expression toxicity assays.
Currently, the company markets Toxbank, along with specialized rat, human, mouse, and custom toxicology microarrays and specialized toxicology assays. Phase-1 is also planning to introduce a ToxBank canine database of gene expression toxicity in dogs, and a rat proteomics toxicology database, as well as other toxicoproteomics products.